Aridis Pharmaceuticals Inc (NASDAQ:ARDS)
| 0.3976 Delayed Data As of Mar 24 |  -0.0124 / -3.02%Today’s Change | 0.35 Today|||52-Week Range 2.77 | -66.31% Year-to-Date |
Latest ARDS News | Press Releases
| Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More Mar 16 / Zacks.com - Paid Partner Content | Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals Mar 14 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 0.41 |
| Today’s open | 0.41 |
| Day’s range | 0.39 - 0.41 |
| Volume | 908 |
| Average volume (3 months) | 1,122,350 |
| Market cap | $14.4M |
Data as of 3:59pm ET, 03/24/2023
Growth & Valuation
| Earnings growth (last year) | -54.71% |
| Earnings growth (this year) | +54.89% |
| Earnings growth (next 5 years) | +51.90% |
| Revenue growth (last year) | +53.50% |
| P/E ratio | NM |
| Price/Sales | 18.66 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CEMIChembio Diagnostics ... | -0.00 | -0.26% |
| NNVCNanoViricides Inc | -0.05 | -3.82% |
| TPSTTempest Therapeutics... | 0.00 | 0.00% |
| CLRBCellectar Bioscience... | -0.06 | -3.90% |
Data as of 3:49pm ET, 03/24/2023
Financials
| Next reporting date | March 30, 2023 |
| EPS forecast (this quarter) | -$0.41 |
| Annual revenue (last year) | $1.5M |
| Annual profit (last year) | -$42.2M |
| Net profit margin | -2,748.73% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Los Gatos, California |
Forecasts
